Barinthus Biotherapeutics plc (NASDAQ:BRNS) Forecasted to Post Q2 2024 Earnings of ($0.46) Per Share

Barinthus Biotherapeutics plc (NASDAQ:BRNS) – Equities research analysts at William Blair increased their Q2 2024 earnings per share estimates for shares of Barinthus Biotherapeutics in a report issued on Monday, May 13th. William Blair analyst A. Hsieh now expects that the company will earn ($0.46) per share for the quarter, up from their previous estimate of ($0.66). The consensus estimate for Barinthus Biotherapeutics’ current full-year earnings is ($2.38) per share. William Blair also issued estimates for Barinthus Biotherapeutics’ Q3 2024 earnings at ($0.48) EPS, Q4 2024 earnings at ($0.50) EPS, FY2024 earnings at ($1.84) EPS, Q1 2025 earnings at ($0.52) EPS, Q2 2025 earnings at ($0.54) EPS, Q3 2025 earnings at ($0.56) EPS, Q4 2025 earnings at ($0.58) EPS, FY2025 earnings at ($2.20) EPS and FY2026 earnings at ($2.39) EPS.

Separately, HC Wainwright restated a “buy” rating and set a $8.00 target price on shares of Barinthus Biotherapeutics in a research report on Thursday.

Barinthus Biotherapeutics Stock Performance

BRNS opened at $2.35 on Thursday. Barinthus Biotherapeutics has a 12 month low of $1.64 and a 12 month high of $5.10. The company has a market cap of $91.46 million, a P/E ratio of -1.28 and a beta of -0.45. The business has a 50 day simple moving average of $2.55.

Barinthus Biotherapeutics (NASDAQ:BRNS) last posted its earnings results on Wednesday, March 20th. The company reported ($0.45) earnings per share for the quarter, topping the consensus estimate of ($0.55) by $0.10.

Institutional Investors Weigh In On Barinthus Biotherapeutics

A hedge fund recently bought a new stake in Barinthus Biotherapeutics stock. BlueCrest Capital Management Ltd bought a new position in shares of Barinthus Biotherapeutics plc (NASDAQ:BRNS) during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 542,673 shares of the company’s stock, valued at approximately $1,292,000. BlueCrest Capital Management Ltd owned 1.39% of Barinthus Biotherapeutics at the end of the most recent quarter. Hedge funds and other institutional investors own 25.20% of the company’s stock.

Barinthus Biotherapeutics Company Profile

Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in development of novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company's development pipeline includes VTP-300, an immunotherapeutic candidate under phase 2 studies as a potential component of a functional cure for chronic hepatitis B virus (HBV) infection; VTP-200, a non-surgical product candidate under phase 2 studies for treating persistent high-risk human papillomavirus (HPV) infection; VTP-1000, an autoimmune preclinical candidate designed to treat patients with celiac disease; VTP-1100 product candidate to target HPV16+ cancers; and VTP-850/850, a second-generation immunotherapeutic candidate under phase 2 studies to treat recurrent prostate cancer.